Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86660
Title:
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.
Authors:
Robertson, Jane D; Nagesh, K; Jowitt, S N; Dougal, Mark; Anderson, Heather; Mutton, K; Zambon, M; Scarffe, J Howard
Abstract:
Vaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 patients underwent vaccination against influenza, S. pneumoniae and Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to vaccination and 4-6 weeks afterwards. Antibody titres against S. pneumoniae and Hib were compared with reference values corresponding to the geometric mean titres of a healthy UK population. For influenza vaccination, haemagglutination inhibition (HI) titres were measured against three inactivated strains; a titre of > or = 1/40 was considered protective. No patient had protective titres to all three antigens prior to vaccination and 41 patients (85%) had titres < 1/40 to all 3 strains. Post vaccination only 9/48 patients (19%) achieved protective antibody titres. Resistance to S. pneumoniae and response to Pneumovax II was also poor: prevaccination, 45 patients (93%) had suboptimal antibody titres and in 26/43 patients (61%) titres remained low post vaccination. Resistance to Hib and response to vaccination was comparable with the healthy adult UK population. These results question the practice of routine influenza and pneumococcal vaccination in myeloma patients.
Affiliation:
Christie Hospital NHS Trust, Withington, Manchester, UK.
Citation:
Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. 2000, 82 (7):1261-5 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Apr-2000
URI:
http://hdl.handle.net/10541/86660
DOI:
10.1054/bjoc.1999.1088
PubMed ID:
10755398
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRobertson, Jane Den
dc.contributor.authorNagesh, Ken
dc.contributor.authorJowitt, S Nen
dc.contributor.authorDougal, Marken
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorMutton, Ken
dc.contributor.authorZambon, Men
dc.contributor.authorScarffe, J Howarden
dc.date.accessioned2009-11-23T10:15:05Z-
dc.date.available2009-11-23T10:15:05Z-
dc.date.issued2000-04-
dc.identifier.citationImmunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. 2000, 82 (7):1261-5 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid10755398-
dc.identifier.doi10.1054/bjoc.1999.1088-
dc.identifier.urihttp://hdl.handle.net/10541/86660-
dc.description.abstractVaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 patients underwent vaccination against influenza, S. pneumoniae and Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to vaccination and 4-6 weeks afterwards. Antibody titres against S. pneumoniae and Hib were compared with reference values corresponding to the geometric mean titres of a healthy UK population. For influenza vaccination, haemagglutination inhibition (HI) titres were measured against three inactivated strains; a titre of > or = 1/40 was considered protective. No patient had protective titres to all three antigens prior to vaccination and 41 patients (85%) had titres < 1/40 to all 3 strains. Post vaccination only 9/48 patients (19%) achieved protective antibody titres. Resistance to S. pneumoniae and response to Pneumovax II was also poor: prevaccination, 45 patients (93%) had suboptimal antibody titres and in 26/43 patients (61%) titres remained low post vaccination. Resistance to Hib and response to vaccination was comparable with the healthy adult UK population. These results question the practice of routine influenza and pneumococcal vaccination in myeloma patients.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntibody Formation-
dc.subject.meshFemale-
dc.subject.meshHaemophilus Infections-
dc.subject.meshHaemophilus Vaccines-
dc.subject.meshHaemophilus influenzae-
dc.subject.meshHumans-
dc.subject.meshImmunocompromised Host-
dc.subject.meshInfluenza Vaccines-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMultiple Myeloma-
dc.subject.meshPneumococcal Infections-
dc.subject.meshStreptococcus pneumoniae-
dc.subject.meshVaccination-
dc.titleImmunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.